ExThera Medical, a leading developer of extracorporeal blood filtration devices, has announced the successful completion of the Phase I OSCAR I STUDY at OU Health Stephenson Cancer Center, a significant milestone in cancer treatment research.
Positive Results from Initial Safety and Efficacy Evaluation
The OSCAR study, a Prospective Single-Arm Feasibility Trial, focused on evaluating the ONCObind Procedure Hemoperfusion Filter's ability to remove Circulating Tumor Cells (CTCs) from patients with metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Five PDAC patients underwent the ONCObind Procedure, exhibiting no safety concerns or adverse signals. Data from the trial has been submitted to the FDA for review to advance to the next phase, OSCAR II, which proposes expanding the patient cohort to include Metastatic Colorectal Cancer (MCRC).
Promising Outcomes and Future Collaborations
Bob Ward, Ph.D., NAE, Chairman, and President of ExThera Medical, expressed satisfaction with the patients' improved sedimentation rates and appetite following the ONCObind Procedure. Dr. Sanja Ilic, Chief Regulatory Officer, emphasized the positive collaboration with Stephenson Cancer Center and the potential for future studies in pancreatic and colorectal cancer.
Innovative Hemoperfusion Technology
The ONCObind Procedure Hemoperfusion Filter, based on the Onco-Seraph platform technology, targets and filters out CTCs in the bloodstream, a crucial step in cancer metastasis. Utilizing ExThera's Seraph® 100 Microbind® Affinity Blood Filter technology, the ONCObind Procedure has shown significant success in reducing CTCs, paving the way for potential therapeutic applications.
About ExThera Medical Corporation
ExThera Medical specializes in extracorporeal blood filtration devices such as the Seraph® 100 Microbind ® Affinity Blood Filter, designed to combat a wide range of pathogens in critically ill patients. With a strong track record in treating severe infections and sepsis, the company's innovative products are positioned to revolutionize patient care.
Conclusion
The successful completion of the OSCAR I study marks a significant step forward in cancer treatment research, showcasing the potential of the ONCObind Procedure in combating metastatic tumors. As ExThera Medical continues to innovate in blood filtration technology, the future holds promising prospects for improving patient outcomes and advancing medical science.